Hugues is the co-founder and serves as a member on our Board of Directors and heads our Executive Committee.

Hugues brings more than fifteen years’ expertise as a serial entrepreneur in the Life Sciences and Biotechnology industries to the global team of experts at Univercells Group. Prior to founding Univercells Group, he acted as CEO at MaSTherCell (a leading CMO for cell therapy acquired by Catalent in 2020), Artelis (an innovator and leader in cell culture process optimization), and Kitozyme (a world-leading manufacturer of vegetable chitosan).

Hugues Bultot holds a master’s degree in law from UCL, Belgium, an executive master’s degree in business administration from Solvay Business School, Belgium, in tax management from ICHEC in Belgium, and certification in innovation from MIT’s Sloan School of Management in the United States.

José is the co-founder and the architect of highly efficient production processes that break the barriers to biomanufacturing. A recognized technology leader in the biopharmaceutical industry, José brings a strong track record in innovative processes design and successful commercialization.

Previous accomplishments include the start-up of Artelis, where he designed and developed bioreactors that transformed industrial operations – the iCellis system being now considered as standard in the vaccines and gene therapy industry. The technology was industrialized at ATMI LifeSciences and Pall Lifesciences, where José held the position of Cell Culture Technologies Director. Prior to Artelis, José was Head of Viral Vaccine Industrialization at GSK Vaccines.

With a background in Chemical Engineering, Jose’s education includes a PhD in Applied Sciences from the Université Libre de Bruxelles, and an entrepreneurship degree from the Solvay Business School.

Matt is Co-Founder and President of Gamma Biosciences LLC, an investment platform formed in partnership with KKR & Co. focused on next-generation bioprocessing technologies and manufacturing for advanced therapies. 

Matt oversees the Gamma portfolio and is responsible for identifying and executing investments as well as driving growth, strategic and operational initiatives across Gamma’s operating companies. Matt was most recently Global Head of Business Development for GE Healthcare, where he was responsible for M&A and strategic alliances across the $19B healthcare division of GE.  Matt joined GE in 2011 and held a variety of other leadership positions in strategy, business development, venture investing and new business creation. 

Matt began his career as a corporate attorney at Sidley Austin LLP.  He holds a J.D. from the University of Michigan and a B.A. in Economics from Georgetown University.

Kugan Sathiyanandarajah (Menlo Park) joined KKR in 2010 and is a member of the Health Care industry team and Head of KKR’s Health Care Strategic Growth business in Europe.

He was previously a member of KKR’s European Private Equity platform, where he held joint responsibility for the Health Care industry team and has played a significant role in KKR’s investments in LGC Group, Walgreens Boots Alliance, Gamma Biosciences, Alvogen and Galenica. He currently serves on the board of directors of Gamma Biosciences and EchoNous.

Prior to joining KKR, he was with Goldman Sachs, where he was a member of the U.K. mergers and acquisitions team. Mr. Sathiyanandarajah earned an M.A. (First Class Hons) in Physical Natural Sciences (Chemistry) from the University of Cambridge.

Anuv Ratan joined KKR in 2017 and is a member of the Health Care industry team. At KKR, he has been involved with investments in Gamma Biosciences, Impel Neuropharma, Headlands Research, BrightSpring Pharmerica, Global Medical Response, Ajax Health, and Aimmune Therapeutics.

He is currently a member of the board of directors of Gamma Biosciences, Blue Sprig Pediatrics, and Headlands Research. Prior to joining KKR, Mr. Ratan was with FFL Partners, where he was involved in a number of health care transactions. Mr. Ratan began his career at The Blackstone Group. He holds an A.B., with honors, in Neurobiology from Harvard University.

Mathias joined Univercells in 2015 as Chief Financial Officer to conduct Univercells’ financial strategy and fundraising activities. Then he acted as a Chief Commercial Officer between May 2017 and 2019 and played a key role in the company’s development and commercialization efforts of its technology portfolio including the scale-X single-use bioreactors range and the NevoLine™ biomanufacturing platform.

Today Mathias serves as CEO at Univercells Technologies where he oversees the company’s operations and leads the company’s strategy development and implementation. It includes the commercialization of the company’s product portfolio as well as new technology developments to further expand the company’s market reach and success.

Mathias brings to the company over 10 years of experience and his dynamic savoir-faire in activities related to business strategy, operations, business planning and fundraising. 

Mathias holds a master in finance from Solvay Business School in Belgium.

Tania D. Pereira Chilima is the Chief Technology Officer at Univercells Technologies where she focuses on driving innovation to execute our mission of making biologics globally available and affordable. She also oversees the direction of the technology portfolio and is responsible for continuously identifying new technologies that could complement our portfolio as well as the application of our systems to new modalities.

Prior to this role, she was Product Manager for the NevoLine™ platform at Univercells, and previously worked as a post-doctorate researcher for the ULTRA grant sponsored by the Bill and Melinda Gates foundation, focused on designing manufacturing strategies for ultra-low-cost vaccine manufacture.

Tania holds an engineering doctorate from the University College London in partnership with Pall Life Sciences entitled, Decisional Tools for Enabling Successful Manufacture and Commercialization of Cell Therapy Products, and is a frequent contributor to industry publications and journals.

Bob joined Univercells Technologies as Chief Operations Officer at the time of its creation in early 2020.  In this role, Bob brings focus to the completion of development of the technology portfolio as well as evolving the organization towards a reliable equipment supplier to the vaccine and gene therapy markets.

Bob brings 30+ years of experience in manufacturing, development and supply chain in plastics and clean assembly for packaging, invasive medical devices, and single-use systems for biopharma.  His experience includes more than a decade with GE and two operating companies of Danaher Corporation. 

Bob has extensive experience in the use of Lean and Six Sigma methodologies to bring efficiency in manufacturing and business processes.

Bob holds his Bachelors, Masters and PhD degrees in Chemical Engineering with focus on polymer processing. 

Gaëlle joined Univercells Technologies in May 2021 as our Chief Financial Officer leading the finance operations and strategies to support the rapid commercial development of the company.

Prior to joining us, her past assignment include working with KKR Capstone – the operational arm of the private equity fund where she spent 5 years in London working with the management of various portfolio companies like Trainline, Telepizza, LGC and many others.

Before joining KKR, Gaëlle got her MBA from Columbia Business School, spent some time at Mckinsey & Company working as a generalist consultant and at BASF as supply chain strategy expert.